Endlyz Therapeutics Inc. and Endlyz UK Ltd (together ‘Endlyz’) are developing disease-modifying therapeutics that restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease and other dementias. By leveraging extensive industry experience, a robust investor syndicate, and academic collaborations that provide access to advanced technologies on an exclusive basis, Endlyz is well positioned to lead the industry in our programmes. The company is open to discuss collaborations and in-licensing of complimentary programmes.
Company Details
- Employees
- 7
- Founded
- 2021
- Address
- Time Split Between London And Oxford.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.endlyz.com
Endlyz Therapeutics Questions
Endlyz Therapeutics's website is http://www.endlyz.com
Endlyz Therapeutics's LinkedIn profile is https://www.linkedin.com/company/endlyztherapeutics
Endlyz Therapeutics has
7 employees.
View email and phone details for 7
employees at Endlyz Therapeutics.
Endlyz Therapeutics's industry is
Biotechnology Research
Endlyz Therapeutics's top competitors are
Sv Health Investors' Dementia Discovery Fund (Ddf),
Isomorphic Labs,
Cd3 - Centre For Drug Design And Discovery,
Sixfold Bioscience,
Greywolf Therapeutics,
Trimtech Therapeutics Limited,
Dark Blue Therapeutics,
Kodiform Therapeutics,
Galatea Bio Inc.,
Artis Biosolutions.
Endlyz Therapeutics's categories are Biotechnology Research
Endlyz Therapeutics's founding year is 2021
